Key result
Warfarin-treated patients with atrial fibrillation have a residual risk of stroke that was compared to patients without atrial fibrillation to distinguish treatment failure from baseline risk.
Why the study?
Is the incidence of stroke in warfarin-treated atrial fibrillation patients attributable to treatment failure or baseline risk compared to similar-risk patients without atrial fibrillation?
Is the incidence of stroke in warfarin-treated atrial fibrillation patients attributable to treatment failure or baseline risk compared to similar-risk patients without atrial fibrillation?
This study aims to determine if residual stroke risk in warfarin-treated atrial fibrillation patients is due to treatment failure or inherent baseline risk.
Residual stroke risk on warfarin in AF warrants caution against assuming treatment failure; leaves open the relative contribution of baseline factors.
This study compares incidence of stroke among patients with warfarin-treated atrial fibrillation with the incidence among similar-risk patients without atrial fibrillation to distinguish if on-treatment stroke is attributable to treatment failure or baseline risk.
No takes yet. Share an insight, caveat, or question.
Freedman et al. (2016) studied this question. Warfarin-treated patients with atrial fibrillation have a residual risk of stroke that was compared to patients without atrial fibrillation to distinguish treatment failure from baseline risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: